Clinical Trial Detail

NCT ID NCT03161431
Title SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Syntrix Biosystems, Inc.
Indications

melanoma

Therapies

SX-682

Pembrolizumab + SX-682

Age Groups: adult senior

No variant requirements are available.